Ultragenyx Launches Restructuring Plan to Cut Costs

Ultragenyx Pharmaceutical ( (RARE) ) has shared an announcement.

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company developing and commercializing therapies for serious rare and ultra-rare genetic diseases, anchored by products such as Crysvita, Dojolvi, Evkeeza and Mepsevii. The company has a meaningful international footprint, including Latin America and Türkiye, and pursues a strategy centered on high-value, first-in-class treatments for underserved patient populations.

For the year ended December 31, 2025, Ultragenyx reported revenue of $673 million, a 20% increase versus 2024, led by Crysvita’s 17% growth to $481 million and strong expansion in Evkeeza, but still posted a net loss of $575 million on $1.2 billion in operating expenses. On February 12, 2026, the company began implementing a strategic restructuring, including a 10% reduction in headcount, or about 130 employees, and the termination of UX143 manufacturing agreements, expecting about $50 million in related charges in the first half of 2026 as it seeks to reduce costs, focus resources on its largest value drivers, and support its stated path to achieving profitability in 2027.

The most recent analyst rating on (RARE) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Ultragenyx Pharmaceutical stock, see the RARE Stock Forecast page.

Spark’s Take on RARE Stock

According to Spark, TipRanks’ AI Analyst, RARE is a Neutral.

The score is held down primarily by weak financial performance—ongoing losses, negative operating/free cash flow, and elevated leverage—despite strong gross margins and revenue growth. Technically, the stock remains in a broader downtrend below key longer-term moving averages with a negative MACD. Offsetting positives include upbeat revenue guidance, nondilutive financing that improves near-term flexibility, and constructive regulatory milestones for key gene therapy programs.

To see Spark’s full report on RARE stock, click here.

More about Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases. Its marketed products include Crysvita, Dojolvi, Evkeeza and Mepsevii, with significant exposure to international markets such as Latin America and Türkiye and a strategy built around high-value rare disease franchises.

In 2025, Ultragenyx generated total revenue of $673 million, up 20% year-on-year, driven by 17% growth in Crysvita to $481 million and strong gains in Evkeeza, though it still reported a net loss of $575 million on operating expenses of $1.2 billion. The company entered 2026 with $737 million in cash and guided 2026 revenues from existing products to $730 million–$760 million, while initiating a strategic restructuring on February 12, 2026 that includes a 10% workforce reduction of about 130 employees and termination of UX143 manufacturing agreements, resulting in an estimated $50 million of charges in the first half of 2026 as it seeks to sharpen focus on key programs and maintain a path to targeted profitability in 2027.

Average Trading Volume: 2,549,060

Technical Sentiment Signal: Sell

Current Market Cap: $2.33B

For an in-depth examination of RARE stock, go to TipRanks’ Overview page.